CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Ganey Tikva, Israel

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

    Phase

    3

    Span

    295 weeks

    Sponsor

    UCB Biopharma SRL

    Bardejov

    Recruiting

  • Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

    Phase

    3

    Span

    119 weeks

    Sponsor

    Arrowhead Pharmaceuticals

    Bardejov

    Recruiting

  • A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

    Phase

    2

    Span

    109 weeks

    Sponsor

    H. Lundbeck A/S

    Bardejov

    Recruiting

  • A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

    The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained chronic cough) at 24 weeks.

    Phase

    3

    Span

    181 weeks

    Sponsor

    Bellus Health Inc. - a GSK company

    Bardejov

    Recruiting

  • A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

    Phase

    2/3

    Span

    621 weeks

    Sponsor

    Sun Pharmaceutical Industries Limited

    Bardejov

    Recruiting

  • EuroPainClinicsStudy X

    The aim of this clinical study is to compare the benefits and complications after minimally invasive spinal procedures in patients with acute lumbosacral radicular syndrome caused by a herniated disc compressing the spinal neural structures. The study only works with patient data provided by the outpatient clinic for research analysis in the EPCS IV clinical study. All patient data are encrypted during collection and evaluation during the study, and stored in an encrypted database. The data will be evaluated by an independent institution - The Institute of Measurement of the Slovak Academy of Sciences.

    Phase

    N/A

    Span

    144 weeks

    Sponsor

    Europainclinics z.ú.

    Bardejov

    Recruiting

  • EuroPainClinicsStudy XI (Cryo vs RF MB Z Joints)

    Description of the clinical state: Facet joint pain encompasses a significant portion of the possible sources of pain in patients with vertebrogenic algic syndrome. A typical symptom caused by facet joint irritation of the medial branch nerve is a back pain with intermittent irregular patchy pain spreading to the legs. The cause of this pain is irritation of the medial branch of the dorsal nerve root which innervates a facet joint. Confirmation of the source of the pain involves local anaesthetic blocks of the medial nerve branches in several adjoining vertebral areas. If this test is positive, then the patient's condition is indicated for radiofrequency ablation or cryoablation of the nerve branches. Description of interventional procedures: Patients with chronic low back pain with confirmed zygapophysial joint pain after previous two medial branch nerve blocks with positive results are indicated for radiofrequency medial neurotomy or alternative cryoablation neurotomy. Navigation with probes in both cases is arranged and directed according to fluoroscopic imaging.

    Phase

    N/A

    Span

    105 weeks

    Sponsor

    Europainclinics z.ú.

    Bardejov

    Recruiting

  • A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

    Phase

    3

    Span

    291 weeks

    Sponsor

    UCB Biopharma SRL

    Bardejov

    Recruiting

  • A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)

    Phase

    3

    Span

    300 weeks

    Sponsor

    Chiesi Farmaceutici S.p.A.

    Bardejov

    Recruiting

  • Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC

    Phase

    3

    Span

    240 weeks

    Sponsor

    Biocad

    Bardejov

    Recruiting

1-10 of 18
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information